Literature DB >> 1517804

Intracranial ependymoma in children: analysis of prognostic factors.

J K Chiu1, S Y Woo, J Ater, J Connelly, J M Bruner, M H Maor, J van Eys, M J Oswald, R Shallenberger.   

Abstract

Between 1955 and 1986, 25 children (aged 2 weeks to 15 years) were treated for intracranial ependymoma at M.D. Anderson Cancer Center. Nine patients had supratentorial primaries (5 high-grade, 4 low-grade), and 16 had infratentorial primaries (9 high-grade, 7 low-grade). Five patients had gross complete resection and 20 had incomplete resection. Seven patients received craniospinal irradiation (25-36 Gy to the neuro-axis, 45-55 Gy to tumor bed), 12 received local field irradiation (29-60 Gy, median 50 Gy). Five infants had adjuvant chemotherapy without radiotherapy, and 6 children had post-radiotherapy adjuvant chemotherapy, and 12 patients had salvage chemotherapy with various agents and number of courses. Eight patients are alive, disease-free and without relapse from 1 year to 12 1/2 years from diagnosis (median 42 months). The primary failure pattern was local recurrence. The data suggest that 1) the long-term cure rate of children with ependymoma is suboptimal; 2) histologic grade may be of prognostic importance for supratentorial tumors; 3) prognosis appears worse for girls and infants under 3 years of age; 4) in well-staged patients routine spinal irradiation could be omitted; 5) the role of adjuvant chemotherapy is unclear.

Entities:  

Mesh:

Year:  1992        PMID: 1517804     DOI: 10.1007/bf00172482

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  29 in total

1.  Ependymoma: a follow-up study of 101 cases.

Authors:  S J Mork; A C Loken
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

2.  Ependymomas and choroid plexus papillomas.

Authors:  N RINGERTZ; A REYMOND
Journal:  J Neuropathol Exp Neurol       Date:  1949-10       Impact factor: 3.685

3.  Calculation of survival rates for cancer.

Authors:  J BERKSON; R P GAGE
Journal:  Proc Staff Meet Mayo Clin       Date:  1950-05-24

4.  Lack of histopathological correlation of malignant ependymomas with postoperative survival.

Authors:  G W Ross; L J Rubinstein
Journal:  J Neurosurg       Date:  1989-01       Impact factor: 5.115

5.  Ependymomas and ependymoblastomas in children.

Authors:  G J Dohrmann; J R Farwell; J T Flannery
Journal:  J Neurosurg       Date:  1976-09       Impact factor: 5.115

Review 6.  Intracranial tumors: response and resistance to therapeutic endeavors, 1970-1980.

Authors:  H J Bloom
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-07       Impact factor: 7.038

7.  Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.

Authors:  T W Pendergrass; J M Milstein; J R Geyer; A F Mulne; E J Kosnik; J D Morris; R L Heideman; F B Ruymann; J T Stuntz; W A Bleyer
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

8.  Ependymomas of childhood. I. Histological survey and clinicopathological correlation.

Authors:  H M Liu; J Boogs; J Kidd
Journal:  Childs Brain       Date:  1976

9.  Intracranial ependymomas in childhood. Survival and functional results of 47 cases.

Authors:  A Pierre-Kahn; J F Hirsch; F X Roux; D Renier; C Sainte-Rose
Journal:  Childs Brain       Date:  1983

10.  Ependymomas: results of radiation treatment.

Authors:  P G Garrett; W J Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-08       Impact factor: 7.038

View more
  21 in total

Review 1.  Pediatric surgical neuro-oncology: current best care practices and strategies.

Authors:  James T Rutka; John S Kuo
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

2.  New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.

Authors:  Karen D Wright; Amar Gajjar
Journal:  Childs Nerv Syst       Date:  2009-02-11       Impact factor: 1.475

3.  Prognostic relevance of localization and grading in intracranial ependymomas of childhood.

Authors:  R I Ernestus; R Schröder; H Stützer; N Klug
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

4.  Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes.

Authors:  Rebecca Senetta; Clelia Miracco; Salvatore Lanzafame; Luigi Chiusa; Rosario Caltabiano; Antonio Galia; Giulia Stella; Paola Cassoni
Journal:  Neuro Oncol       Date:  2010-11-08       Impact factor: 12.300

5.  Patterns of relapse for children with localized intracranial ependymoma.

Authors:  Brian De; Yasmin Khakoo; Mark M Souweidane; Ira J Dunkel; Suchit H Patel; Stephen W Gilheeney; Kevin C De Braganca; Matthias A Karajannis; Suzanne L Wolden
Journal:  J Neurooncol       Date:  2018-03-06       Impact factor: 4.130

Review 6.  Initial management of childhood brain tumors: neurosurgical considerations.

Authors:  Farideh Nejat; Mostafa El Khashab; James T Rutka
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 7.  Survival following treatment for intracranial ependymoma: a review.

Authors:  G Tamburrini; M D'Ercole; B L Pettorini; M Caldarelli; L Massimi; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2009-04-22       Impact factor: 1.475

8.  Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).

Authors:  Dayron Rodríguez; Michael C Cheung; Nadine Housri; Alfredo Quinones-Hinojosa; Kevin Camphausen; Leonidas G Koniaris
Journal:  J Surg Res       Date:  2009-05-14       Impact factor: 2.192

9.  The history of ependymoma management.

Authors:  Kyu-Won Shim; Dong-Seok Kim; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2009-05-21       Impact factor: 1.475

10.  Ependymomas: MIB-1 proliferation index and survival.

Authors:  A M Ritter; K R Hess; R E McLendon; L A Langford
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.